Welcome to our dedicated page for Omeros news (Ticker: OMER), a resource for investors and traders seeking the latest updates and insights on Omeros stock.
Omeros Corporation develops and commercializes protein and small-molecule therapeutics for large-market and orphan indications, with emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its news centers on YARTEMLEA (narsoplimab-wuug), an FDA-approved MASP-2 lectin pathway inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adult and pediatric patients aged two years and older.
Recurring updates also cover U.S. commercialization, reimbursement coding, transplant-medicine presentations, operating and financial results, and pipeline work including OMS1029, a long-acting MASP-2 inhibitor, and OncotoX-AML, an oncology therapeutic platform targeting acute myeloid leukemia.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.